level [11, 12] . Specific host genetic factors have also been associated with the efficiency of CD4 + T cell recovery, including copy numbers of the chemokine (C-C motif) ligand 3-like 1 [13] , polymorphisms in genes related to expression of chemokine (C-C motif) receptor 5 [13] , genes for cytokines and other chemokines [14, 15] , and genes for apoptosis and cell survival [14, 15] . IL-7 is an important nonredundant cytokine that is essential for regulating the proliferation and survival of circulating naive and memory T cells [16] . The IL-7 receptor (IL-7R) consists of the high-affinity a chain (CD127) and the common cytokine g chain (CD132). IL-7 also binds to soluble IL-7Ra (sIL-7Ra), which may limit availability for IL-7 to mediate its effects on T cells [17, 18] . Mutations in the IL-7Ra gene may lead to functional impairment of T cell homeostasis [19, 20] .
There are 4 common haplotypes of the IL-7Ra gene [21] . The haplotypes that contain thymine at position rs11567685 have been associated with the primary progressive form of multiple sclerosis [22] . In addition, haplotype 2, which contains thymine at exon 6 (rs6897932), is protective against multiple sclerosis [23, 24] and has been associated with a decrease in the ratio of messenger RNA encoding sIL-7Ra to that encoding membrane-bound IL-7Ra [22, 23, 25] . Another recent study of patients with multiple sclerosis found an association between IL-7Ra haplotype 4 and increased concentration of recent thymic emigrants and IL-7Ra expression on T cells, further demonstrating the potential importance of IL-7Ra genotypes in T cell homeostasis [26] .
We hypothesized that the IL-7Ra genotype has a considerable impact on CD4 + T cell recovery after ART. Our specific aim was to determine the relative importance of persisting immune activation and factors associated with IL-7 homeostasis, specifically the 4 common haplotypes of the IL-7Ra gene, on the extent of CD4 + T cell recovery in a large clinic-based population of patients receiving long-term suppressive ART. Using multivariate analysis, we examined both clinical and biological factors associated with time to achieve CD4 + T cell counts of 1500 and 1200 cells/mL.
MATERIALS AND METHODS

Patient recruitment.
Patients were recruited at 2 sites: the Alfred Hospital and the Melbourne Sexual Health Centre (Melbourne, Australia). Inclusion criteria were as follows: age у18 years, naive to ART, ART first commenced at a CD4 + T cell count of !500 cells/mL and consisting of at least 3 antiretroviral agents, controlled viral replication (HIV RNA load, р500 copies/mL as measured by branched DNA 2.0 assay or !400 copies/ mL as measured by branched DNA 3.0 or polymerase chain reaction-based assay) within 6 months of starting ART, and sustained viral control for at least 12 months. Patients receiving treatment for seroconversion illness or receiving interleukin 2, hydroxyurea, prednisolone, or HIV therapeutic vaccines were excluded. A blood sample was collected at 1 post-ART time point, and plasma and peripheral blood mononuclear cells were stored. Plasma samples collected prior to initiation of ART were obtained from sample repositories. Both pre-ART and post-ART samples were collected and processed using identical protocols within 24 h of collection. The study protocol was approved by the ethics committee of Alfred Health, and all patients provided written informed consent. HIV-negative plasma samples were obtained from laboratory staff.
Plasma LPS, soluble CD14 (sCD14), and IL-7 cytokine determination. Microbial translocation was estimated by measurement of LPS levels by use of a commercial chromogenic limulus amebocyte lysate assay (Lonza), sCD14 levels by use of the Quantikine sCD14 enzyme-linked immunosorbent assay (R&D Systems), and IL-7 levels by use of the IL-7 highly sensitive Quantikine enzyme-linked immunosorbent assay (R&D Systems). Because of the significant interassay variability of the LPS assay (coefficient of variation, 27%) and the low intraassay variability (coefficient of variation, !5%), samples from the same patient (eg, pre-ART and post-ART samples or samples for the kinetic analyses) were always assayed on the same plate in duplicate.
IL-7Ra genotyping and sIL-7Ra measurement. The 4 common IL-7Ra promoter haplotypes were identified by haplotypetagging single-nucleotide polymorphisms (SNPs) as described elsewhere [21] . The rs11567686 SNP (A/G) tags haplotype 1, the rs6897932 SNP (C/T) tags haplotype 2, the rs7718919 SNP (G/ T) tags haplotype 3, and the rs11567685 SNP (T/C) tags haplotype 4. Soluble IL-7Ra levels were measured as described elsewhere [27] .
Statistical analysis. For the cohort analysis, the multivariate Cox proportional hazards model was used to identify determinants of immune reconstitution following suppressive ART, with time taken to achieve CD4 + T cell counts of 1500 and 1200 cells/mL used as the primary endpoints. All measures of HIV RNA load from the baseline levels were included as time-dependent covariates to allow appropriate model adjustment if patients developed virological failure (defined as 2 consecutive HIV RNA loads of 1400 copies/mL) after recruitment.
For the kinetic analysis, 30 patients were randomly selected from the cohort with the use of a random number table. Samples were obtained at 6 and 12 months after ART initiation and yearly thereafter. The overall rate and kinetics of the decline in LPS and sCD14 levels were assessed. Two basic models of decay were tested as shown: model 1 (exponential decay), ; model 2 (exponential decay with plateau),
The parameters were as follows:
Ϫdt V(t) p P + (P Ϫ P)e 1 0 1 LPS or sCD14 level at time t (measured in months after ART); P 0 , initial level of LPS or sCD14 (models 2 and 1); P 1 , plateau level of LPS or sCD14 (model 2); d, decay rate (models 1 and 2).
Each model was fitted with 2 methods in the statistical program R (version 2.10.1; http://www.r-project.org) and r-library nlme as follows: First, the model was fitted to the data pooled over all patients. Second, the model was fitted as a randomeffects model, which assumes a mean model fit and accounts for individual patient variation in parameters. The fit for each model was tested using the anova function (in R), which determines the best-fit model by use of log-likelihood and the number of parameters.
RESULTS
Patient details.
We recruited 106 patients, and pre-ART plasma samples were available for 96 patients. Clinical details of the patients are described in Table 1 . After initiation of ART, all patients had viral suppression (HIV RNA load, !400 copies/ mL) throughout the follow-up period except 6 patients who developed a single episode of virological failure. The median HIV RNA load at virological failure was 10,000 copies/mL (interquartile range [IQR], 1200-64,975 copies/mL). All patients subsequently achieved complete viral suppression.
Changes in LPS, sCD14, and IL-7 cytokine levels following suppressive ART. The effects of long-term suppressive ART on microbial translocation and immune activation were assessed in plasma samples of patients before and at 1 time point after at least 12 months of suppressive ART. Both LPS and sCD14 levels were significantly reduced with treatment (P ! for both) ( Figures 1A and 1B ) but remained significantly .001 elevated compared with those of uninfected control participants ( and , respectively) ( Figures 1A and 1B ). We P p .026 P ! .001 found a significant correlation between sCD14 and LPS levels ( ; ) ( Figure 1D ) and between the magnitude R p 0.381 P ! .001 of the post-ART change in sCD14 level and that of the change in LPS level ( ; ) ( Figure 1E ). Post-ART IL-R p 0.238 P p .020 7 levels were not different from those of uninfected control participants ( Figure 1C ).
Declining trend of LPS and sCD14 levels following longterm suppressive highly active ART. We then sought to assess the rate and pattern of decline in LPS and sCD14 levels following initiation of ART in a subset of 30 patients. All patients had viral suppression (median no. of viral load assays per patient per year, 5; IQR, 4-6) throughout the follow-up period (median follow-up time, 6.5 years; IQR, 3.8-10.0 years). The median baseline CD4 + T cell count was 143 cells/mL (IQR, 32-332 cells/mL), and the median baseline HIV RNA level was ). The solid lines represent the mean fit for the optimal mixed effects model (exponential decay with plateau for LPS levels and n p 30 exponential decay for sCD14 levels). The best-fit model (which optimizes the compromise between the number of parameters and model error) occurred for patients who shared the same mean decay rate but had variable initial amounts (and variable plateau values where applicable). The dashed lines show individual patient fits for the best-fit model. Some individual patient fits are poor descriptions of the data, indicating that the variability in LPS or sCD14 levels is larger than the underlying mean population decay in LPS or sCD14 levels. The LPS half-life (for the exponential only model) was 336 months ( ) and 438 months ( ) for the pooled and random-effects fit, respectively; whereas the sCD14 half-life (for the exponential P p .005 P p .002 model) was 563 months ( ) and 714 months ( ) for the pooled and random-effects fit, respectively. P values indicate the statistical P p .018 P p .037 significance of nonzero slope (2-tailed tests). sCD14 for each individual patient across time (Figures 2A and  2B ). The rate of decline was analyzed with an exponential decay model fitted to the data pooled across patients and an exponential decay random-effects model that accounted for variability in parameters across each patient. LPS and sCD14 levels declined significantly with time ( for both LPS and P ! .05 sCD14; 2-tailed test).
LPS levels eventually plateau at a level not significantly different from that in uninfected control participants. The kinetics of decay in LPS and sCD14 levels were then determined by comparing 2 basic models of decay: an exponential model (model 1), in which levels eventually decayed to 0; and an exponential with plateau model (model 2), in which the population experienced exponential decay but plateaued at a level of 10. Due to the large variability across each patient, we assessed these models using random effects. We found that for models 1 and 2, the best fit occurred for patients who had identical decay rates but variable initial and/or plateau levels (that is, we modeled random effects for initial and/or plateau levels only). Model 2 fitted significantly better than model 1 for LPS levels ( ) (Figure 2A ), indicating that the decay P p .047 in LPS levels (half-life, 162 months) eventually reached a plateau with a mean value of 66 pg/mL (95% confidence interval, 25-107 pg/mL) in this patient subset. This level was not significantly different from the levels measured in uninfected control participants ( ; mean ‫ע[‬ standard deviation {SD}], n p 12 pg/mL). Model 2 did not fit significantly better than 35.5 ‫ע‬ 11 model 1 for sCD14 levels, indicating that sCD14 levels decayed exponentially (without plateau) during the time frame studied (6-132 months after ART).
In summary, our kinetic analysis showed that there was a high degree of variation in the levels of LPS and sCD14 measured yearly in patients receiving suppressive ART. In the time frame studied (6-132 months after ART), both the level of LPS and the level of sCD14 exhibited a slow exponential decline. The model predicted that LPS levels would eventually plateau at levels similar to those in uninfected control participants. We are unable to predict whether a plateau occurs for sCD14 levels beyond the time period studied.
Univariate and multivariate analysis. To assess which clinical and biological factors were predictive of immune reconstitution following suppressive ART, survival analysis was performed with 2 defined endpoints: time to achieve a CD4 + T cell count of 1500 cells/mL and time to achieve a CD4 + T cell count of 1200 cells/mL.
In the multivariate analysis, factors that were found to independently predict faster CD4 + T cell recovery to counts of 1500 cells/mL were higher baseline CD4 + T cell count, younger age, lower pre-ART LPS level, higher pre-ART sCD14 level, lower pre-ART IL-7 level, and IL-7Ra haplotype 2 ( Table 2) . Haplotype 2 (which included both homozygous patients [12%] and heterozygous patients [88%]) was significantly associated with more rapid immune recovery ( ) ( Figure 3A ). The P p .007 effect of the IL-7Ra haplotype was most apparent after ∼500 d of suppressive ART.
The analysis of the time to achieving a CD4 + T cell count of 1200 cells/mL was restricted to 51% of the cohort ( ) n p 49 who initiated ART at a CD4 + T cell count of !200 cells/mL and had a median baseline CD4 + T cell count of 107 cells/mL (IQR, 31-153 cells/mL). In the multivariate analysis, higher baseline CD4 + T cell count and lower pre-ART LPS level remained significant predictors of faster reconstitution to CD4 + T cell counts of 1200 cells/mL. In addition, the absence of concurrent trimethoprim and sulfamethoxazole therapy at ART initiation was also significant ( Table 3) .
Soluble IL-7Ra levels are significantly lower in individuals homozygous for haplotype 2 compared with levels in nonhaplotype 2 carriers. Previous studies of HIV-uninfected patients have demonstrated that individuals who are homozygous for haplotype 2 have lower levels of sIL-7Ra [27] , which may alter the availability of IL-7 [18] . Because sIL-7Ra levels may also be altered by HIV infection itself [17, 18, 28] , we measured levels of sIL-7Ra in post-ART plasma samples from HIV-infected patients who were homozygous for haplotype 2 (n p ) and from HIV-infected non-haplotype 2 carriers ( ) 11 n p 22 who were matched for plasma IL-7 levels (mean ‫ע[‬ SD] for haplotype 2, pg/mL; mean ‫ע[‬ SD] for non-hap-3.75 ‫ע‬ 3.66 lotype 2, pg/mL) and CD4 + T cell counts (mean 3.84 ‫ע‬ 3.77 ‫ע[‬ SD] for haplotype 2, cells/mL; mean ‫ע[‬ SD] for 651 ‫ע‬ 205 non-haplotype 2, cells/m)-2 factors that have been 643 ‫ע‬ 223 shown to influence IL-7Ra expression [29] . Consistent with the results of previous studies of HIV-uninfected populations [27] , sIL-7Ra levels were significantly lower in patients homozygous for haplotype 2 than those in non-haplotype 2 carriers ( ) ( Figure 3B ). P ! .001
DISCUSSION
CD4 + T cell reconstitution is highly variable after long-term suppressive ART. In a large clinic-based prospective study, we found that the factors associated with time to achieving CD4 + T cell counts of 1500 and 1200 cells/mL differed. In a multivariate analysis controlling for clinical and biological variables, we found that the factors associated with faster time to CD4 + T cell counts of 1500 cells/mL included higher baseline CD4 + T cell count, younger age, lower pre-ART LPS level, higher pre-ART sCD14 level, lower pre-ART IL-7 level, and the IL-7Ra haplotype 2. We also found lower sIL-7Ra levels in patients homozygous for haplotype 2 compared with those in nonhaplotype 2 carriers. Lower sIL-7Ra levels in haplotype 2 carriers could potentially facilitate increased binding of IL-7 to T cells, leading to more efficient IL-7 activity. Taken together, these data suggest that the IL-7Ra genotype may be an important determinant of long-term immune reconstitution following ART.
Our finding of an association between faster time to achieving CD4 + T cell counts of 1500 cells/mL and IL-7Ra haplotype 2 adds strong support to the likely significant role played by the IL-7-IL-7R axis in CD4 + T cell recovery. Haplotype 2 carries thymine at position rs6897932 on exon 6 of the IL-7Ra gene that encodes the IL-7Ra transmembrane domain [30] . The wild-type allele with cytosine at this position enhances exon skipping and has been associated with a 2-fold increase in the production of messenger RNA encoding sIL-7Ra versus the membrane-bound IL-7Ra [23, 25] . Consistent with the results of previous gene expression studies of HIV-uninfected patients with multiple sclerosis [23, 25, 27] , we found lower sIL-7Ra levels in HIV-infected individuals homozygous for haplotype 2 compared with those in non-haplotype 2 carriers. Heterozygous haplotype 2 carriers have also been shown to have a lower sIL-7Ra concentration, but it is higher than that seen in ho- mozygous haplotype 2 carriers [27] . Haplotype 2 has not been shown to significantly alter the expression of membrane-bound IL-7Ra on total T cells in HIV-uninfected patients [25, 27] , but it is currently unknown whether this is different in the setting of HIV infection.
Recent studies have shown that sIL-7Ra in plasma binds to IL-7 with a similar affinity to membrane-bound IL-7Ra, which suggests that sIL-7Ra may play a role in modulating IL-7 availability [17] . The lower production of sIL-7Ra that is associated with IL-7Ra haplotype 2 may therefore lead to greater availability of IL-7 to bind to the membrane-bound receptor. Given the already reduced expression of membrane-bound IL-7Ra and impaired signaling through this receptor in HIV-infected patients [31] [32] [33] [34] , minor changes to the availability of IL-7 may lead to considerable improvements in homeostatic mechanisms that allow faster normalization of CD4 + T cell counts with ART.
Our finding of IL-7 normalization following ART is consistent with the results of some studies [9, 35] but not with those of others [34, 36] . The difference in results may be because one study was cross-sectional [36] and the other had a followup period of only 12 months after ART [34] . In contrast, the mean duration of time receiving ART in our study was 40 months. We found that lower pre-ART IL-7 levels were associated with faster CD4 + T cell recovery to counts of 1500 cells/ mL, independent of baseline CD4 + T cell counts. In untreated patients, increased IL-7 levels are usually negatively correlated with CD4 + T cell counts [9, 37] . Increased IL-7 levels have been shown to down-regulate IL-7Ra expression on CD4 + and CD8 + T cells [38] . It is therefore conceivable that lower pre-ART IL-7 levels were associated with higher expression of IL-7Ra, potentially leading to enhanced response to endogenous IL-7. Lower pre-ART IL-7 levels have also been found to correlate with improved thymic function as measured by thymic volume and the number of recent thymic emigrants, which would also promote more efficient CD4 + T cell recovery to counts of 1500 cells/mL [39] . In that study [39] , low IL-7 levels were associated with larger pre-ART thymic volumes but smaller increases in thymic volume following ART. Therefore, the role of endogenous IL-7 levels in immune recovery in this setting still remains unclear.
We found that lower pre-ART LPS levels were significantly associated with faster CD4 + T cell recovery to counts of 1500 cells/mL. Pre-ART LPS levels likely reflect the extent of gastrointestinal lymphoid tissue damage sustained in the absence of ART. The extent of damage to gastrointestinal lymphoid tissue prior to initiation of ART may drive the degree of chronic immune activation and its deleterious effects such as the destruction of the lymph node architecture, thymic dysfunction, and drainage of the naive CD4 + T cell pool [40, 41] -consequences that have all been shown to impair CD4 + T cell recovery with treatment [10, 41, 42] .
We surprisingly found that higher baseline sCD14 levels were associated with faster CD4 + T cell recovery to counts of 500 cells/mL. Although the effect size of this paradoxical association in the multivariate analysis was small (for every 100,000-U increase in sCD14 levels, the rate to achieve CD4 + T cell counts of 1500 cells/mL increased by 4.0%), the association was nevertheless highly significant ( ). Although the level of P ! .001 sCD14 has been shown to correlate with that of LPS as well as markers of T cell activation [12] , the biological relationship between sCD14 and LPS is complex. Experiments in vitro and in mice have shown that sCD14 can exert both pro-inflammatory and anti-inflammatory actions, depending on circulating levels of LPS and LPS-binding protein [43, 44] . At high ratios of sCD14 level to LPS-binding protein level, there was inhibition of the LPS effect [45, 46] . Therefore, it is possible that high levels of sCD14 may exert some degree of protection against LPS-induced immune activation. In addition, the availability of LPS to interact with sCD14 may also be influenced by circulating levels of anti-LPS antibodies (anti-endotoxin core antibodies) [47] , which were not assessed in our cohort. A full understanding of LPS-driven immune activation in this setting would require a multivariate analysis of all these parameters.
The determinants of CD4 + T cell recovery to counts of 1500 and 1200 cells/mL were different. Higher baseline CD4 + T cell counts and lower pre-ART LPS levels were associated with faster recovery to CD4 + T cell counts of 1200 and 1500 cells/mL. The absence of concurrent trimethoprim and sulfamethoxazole therapy with ART was found to be significant only for recovery to cells counts of 1200 cells/mL. The slower rate of early CD4 + T cell recovery that is associated with the use of concurrent trimethoprim and sulfamethoxazole therapy at ART initiation has been reported elsewhere [48] . Together, trimethoprim and sulfamethoxazole suppress bone marrow function and likely reduce de novo T cell production [49] . Assessment of CD4 + T cell percentages in this setting may have been helpful, but this parameter was not available for all patients in this study.
In the multivariate analyses for time to achieve CD4 + T cell counts of 1500 and 1200 cells/mL, the levels of LPS and sCD14 while receiving ART were not associated with the efficiency of CD4 + T cell recovery. Prior studies have shown that the degree of residual microbial translocation after ART is associated with the degree of immune restoration [11, 12] . Our findings may be different from those of previous studies for several reasons. First, we used a different method from those used in previous studies to define the outcome of immune reconstitution. In our study, we measured the time to achieve a clinically important CD4 + T cell count, whereas in previous studies, CD4 + T cell reconstitution was measured as the change in CD4 + T cell count from baseline [11, 12] . We believe that our approach is more robust because it takes into account the heterogeneity in both the rate and magnitude of CD4 + T cell count increase.
In addition, measurement of just the magnitude of increase in CD4 + T cell count may be inaccurate in individuals who have achieved a plateau, which is well described following ART [4, 5] . Second, patients in these previous studies were followed up for a relatively shorter median duration after ART compared with the follow-up time our study (12 months [12] and 28 months [11] vs 40 months in this study). Although LPS and sCD14 levels significantly declined but did not normalize post-ART as previously reported [11, 12] , our kinetic model for LPS predicted that the levels of LPS would eventually plateau at levels seen in uninfected control participants, which is consistent with functional restoration of the gastrointestinal lymphoid tissue [50] . Taken together, these data suggest that ongoing microbial translocation in patients receiving ART may not be an important factor limiting long-term CD4 + T cell recovery. There were a number of important limitations to our study. First, although this was a longitudinal study, patients were enrolled and post-ART samples were obtained at varying time points following ART initiation. We adjusted for time between initiating ART and sample collection in the multivariate model, but our results could be confounded by survival bias. Second, a subset of patients were assessed for factors associated with time to achieving CD4 + T cell counts of 1200 cells/mL, and therefore this analysis had less power than the analysis for at Monash University on May 28, 2011 jid.oxfordjournals.org Downloaded from factors associated with time to achieving CD4 + T cell counts of 1500 cells/mL. Finally, although there is a plausible biological basis to support our findings of an association between IL-7Ra haplotype 2 and faster recovery of CD4 + T cells to counts of 1500 cells/mL, this genetic association should be examined in another unrelated cohort.
In summary, we demonstrate that the time to achieve a CD4 + T cell count of 1500 cells/mL in patients receiving long-term suppressive ART was associated with multiple biological parameters including pre-ART LPS level, sCD14 level, and IL-7 level and IL-7Ra haplotype, which suggests that IL-7-driven homeostasis plays an important role in long-term CD4 + T cell recovery. The levels of LPS and sCD14 while receiving ART were not associated with time to CD4 + T cell counts of 1500 or 1200 cells/mL. These findings may have implications for the use of immune-based therapies such as IL-7. Genetic markers, specifically the IL-7Ra genotype, could potentially be incorporated into future algorithms to individualize the optimal time for ART initiation.
